Figures computed from official regulatory filings — .
Analysttarget 6.57 USD (+229%)
Ownershipinsiders 14.14% · institutions 76.67% · short 6.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Foghorn Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys8 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Gallagher Neil | AwardD (derivative) | $114.2K | SEC |
| Lynch Thomas J. Jr. | AwardD (derivative) | $114.2K | SEC |
| SMITH IAN F | AwardD (derivative) | $114.2K | Unusual size | SEC |
| Mendelsohn Michael | AwardD (derivative) | $114.2K | Unusual size | SEC |
| Cole Douglas G. | AwardD (derivative) | $114.2K | Unusual size | SEC |
| Biller Scott | AwardD (derivative) | $114.2K | Unusual size | SEC |
| GILL SIMBA | AwardD (derivative) | $114.2K | Unusual size | SEC |
| PARSHALL B LYNNE | AwardD (derivative) | $114.2K | SEC |
| Duty Stuart | AwardD (derivative) | $114.2K | SEC |
| GOTTSCHALK ADRIAN | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOTTSCHALK ADRIAN | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOTTSCHALK ADRIAN | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOTTSCHALK ADRIAN | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maynard Ryan D | AwardD (derivative) | $2.3M | SEC |
| GOTTSCHALK ADRIAN | AwardD (derivative) | $5.6M | Unusual size | SEC |
| Rivkin Anna | AwardD (derivative) | $942.2K | SEC |
| LaCascia Michael | AwardD (derivative) | $1.7M | Unusual size | SEC |
| Cardama Alfonso Quintas | AwardD (derivative) | $1.7M | Unusual size | SEC |
| Bellon Steven F. | AwardD (derivative) | $1.7M | Unusual size | SEC |
| Costa Carlos | AwardD (derivative) | $1.3M | Unusual size | SEC |
| Flagship Ventures Opportunities Fund I General Partner LLCtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flagship Ventures Opportunities Fund I General Partner LLCtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flagship Ventures Opportunities Fund I General Partner LLCtrack record | AwardD (derivative) | $15M | SEC |
| PARSHALL B LYNNE | AwardD (derivative) | $119.8K | SEC |
| SMITH IAN F | AwardD (derivative) | $119.8K | Unusual size | SEC |